Physician profile
Ali Kutom
NPI 1316912918
$9,741.42
in general payments reported to CMS, 2019-2025
34 companies · $698 in 2025
The $698 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $1,013 · 2021: $1,544 · 2022: $1,705 · 2023: $1,219 · 2024: $2,557 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,640.62 | 2019-2025 | Esprit, Mitraclip, Perclose Prostyle |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,013.75 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,004.05 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $988.88 | 2019-2024 | Xarelto, Opsumit |
| Penumbra, INC. | $841.75 | 2022-2025 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $686.12 | 2019-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $644.84 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $487.37 | 2019-2024 | Farxiga |
| Pfizer INC. | $478.71 | 2020-2025 | |
| Edwards Lifesciences Corporation | $380.15 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $333.58 | 2021-2025 | Verquvo |
| Heartflow, INC. | $155.52 | 2024-2025 | |
| Endologix LLC | $145.11 | 2024 | Torus Stent Graft System, Endocross Device |
| Amgen INC. | $141.54 | 2019-2025 | Repatha |
| Novo Nordisk INC | $102.32 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $83.17 | 2021-2023 | Onyx Frontier |
| Baxter Healthcare | $75.01 | 2024 | Biopharma Sol - Contract Manuf |
| Lexicon Pharmaceuticals, INC. | $60.84 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $46.68 | 2023-2024 | Opsumit, Uptravi |
| Genentech USA, INC. | $44.32 | 2019 | |
| Lilly USA, LLC | $42.11 | 2025 | Zepbound, Mounjaro |
| Shockwave Medical, INC | $41.59 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $39.56 | 2022 | |
| Cardiovascular Systems INC. | $37.27 | 2021 | |
| Thrombolex, INC. | $35.85 | 2025 | Bashir Endovascular Catheter |
| Biotronik INC. | $28.60 | 2025 | Amvia Edge |
| W. L. Gore & Associates, INC. | $23.38 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Amarin Pharma, INC. | $22.39 | 2019 | |
| Surmodics, INC. | $22.24 | 2024 | Pounce Venous Thrombectomy System |
| Tactile Systems Technology INC | $21.69 | 2024 | Flexitouch Plus, Entre Plus |
| Glaxosmithkline, LLC. | $21.15 | 2025 | Shingrix |
| Regeneron Healthcare Solutions, INC. | $18.96 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.58 | 2024 | Arcalyst |
| Angiodynamics, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Kutom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.